Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators

2018 ◽  
Vol 261 ◽  
pp. 130-133 ◽  
Author(s):  
Milton Packer
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Dose Response ◽  
Large Scale ◽  
Novel Approach

scholarly journals Network-based characterization of disease–disease relationships in terms of drugs and therapeutic targets

2020 ◽  
Vol 36 (Supplement_1) ◽  
pp. i516-i524
Author(s):  
Midori Iida ◽  
Michio Iwata ◽  
Yoshihiro Yamanishi
Keyword(s):  
Large Scale ◽  
Expression Patterns ◽  
Therapeutic Targets ◽  
Molecular Networks ◽  
Supplementary Information ◽  
New Associations ◽  
Disease States ◽  
Molecular Features ◽  
Novel Approach

Abstract Motivation Disease states are distinguished from each other in terms of differing clinical phenotypes, but characteristic molecular features are often common to various diseases. Similarities between diseases can be explained by characteristic gene expression patterns. However, most disease–disease relationships remain uncharacterized. Results In this study, we proposed a novel approach for network-based characterization of disease–disease relationships in terms of drugs and therapeutic targets. We performed large-scale analyses of omics data and molecular interaction networks for 79 diseases, including adrenoleukodystrophy, leukaemia, Alzheimer's disease, asthma, atopic dermatitis, breast cancer, cystic fibrosis and inflammatory bowel disease. We quantified disease–disease similarities based on proximities of abnormally expressed genes in various molecular networks, and showed that similarities between diseases could be explained by characteristic molecular network topologies. Furthermore, we developed a kernel matrix regression algorithm to predict the commonalities of drugs and therapeutic targets among diseases. Our comprehensive prediction strategy indicated many new associations among phenotypically diverse diseases. Supplementary information Supplementary data are available at Bioinformatics online.

Single-dose and dose-response studies with oral pirbuterol, a new beta agonist in chronic heart failure

1981 ◽  
Vol 102 (3) ◽  
pp. 578-583 ◽  
Author(s):  
Rudolph Canepa-Anson ◽  
J.Rex Dawson ◽  
Peiliang Kuan ◽  
Carole A. Warnes ◽  
Philip A. Poole-Wilson ◽  
...  
Keyword(s):  
Heart Failure ◽  
Single Dose ◽  
Chronic Heart Failure ◽  
Dose Response ◽  
Beta Agonist

scholarly journals The role of compliance in the treatment of chronic heart failure and the ways to improve it

2021 ◽  
Vol 24 (3) ◽  
pp. 4-13
Author(s):  
Natalia S. Meshcherina ◽  
Elena M. Khardikova ◽  
Nina K. Gorshunova ◽  
Natalia V. Abrosimova ◽  
Tatyana S. Leontieva
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Clinical Guidelines ◽  
Large Scale ◽  
Positive Impact ◽  
Treatment Compliance ◽  
Good Clinical Practice ◽  
Patient Registries ◽  
Physician Compliance ◽  
Scientific Practical

Despite the development and implementation of clinical guidelines, emergence of modern effective drugs for the treatment of chronic heart failure (CHF), this pathology is characterized by stable progression, directly worsening the quality of life and decreasing the life expectancy. With that, treatment efficacy directly depends on high treatment compliance in patients with CHF both at the treatment start and upon its subsequent correction. One should also not underestimate the value of patient readiness to modify their lifestyle. Besides, the complete physician compliance with clinical guidelines also plays a significant role. The absence of correspondence between principles defined in the guidelines and really administered drugs excludes the possibility of achieving control over CHF symptoms and positive impact on the prognosis. This review is aimed at evaluating treatment compliance among both patients with CHF and their physicians with a focus on Russian studies and good clinical practice (GCP) compared to studies of foreign authors. Unfortunately, the problem of compliance in CHF in the Russian Federation has not been sufficiently analyzed in large-scale studies up to the present time: CHF patient registries mainly allow to detect clinical and epidemiological disease features, while almost not covering compliance issues. It should also be noted that the problem of compliance in both physicians and patients is undoubtedly up-to-date, as it often defines further prognosis in patients with CHF, which explains the scientific practical value of large trials with subsequent thorough analysis and searches regarding increasing its efficiency.

Sign in / Sign up

Export Citation Format

Share Document